API | zabofloxacin

zabofloxacin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Zabofloxacin (DW-224a) is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria. It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics. ^Wikipedia

Chemistry

SMILES: CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2
InChIKey: ZNPOCLHDJCAZAH-OEAKJJBVSA-N
Mol. Mass: 401.4
ALogP: 0.98 Partition coefficient
ChEMBL Molecule:
zabofloxacin

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA gyrase subunit A (Escherichia coli K-12) ^UniProt
- DNA gyrase subunit B (Escherichia coli K-12) ^UniProt
- B subunit of DNA gyrase (Escherichia coli) ^UniProt
- DNA topoisomerase 4 subunit A (Escherichia coli K-12) ^UniProt
- DNA topoisomerase 4 subunit B (Escherichia coli K-12) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

dw224a | dw-224a | zabofloxacin

Organizations (29)

Research & Development (29)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Community-Acquired Infections (Phase 2)

Healthy Volunteers (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 29

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue